Identification and functional validation of PNAs that inhibit murine CD40 expression by redirection of splicing

Nucleic Acids Research

Volumn 32, Issue 9, 2004, Pages 2695-2706

  Siwkowski, Andrew M ^a   Malik, Leila ^a   Esau, Christine C ^a   Maier, Martin A ^a   Wancewicz, Edward V ^a   Albertshofer, Klaus ^a   Monia, Brett P ^a   Bennett, C Frank ^a   Eldrup, Anne B ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; INTERLEUKIN 12; ISIS 208529; ISIS 256644; ISIS 256645; ISIS 256646; ISIS 278518; ISIS 278519; ISIS 278520; ISIS 278521; ISIS 278522; ISIS 278523; ISIS 278524; ISIS 278525; ISIS 278526; ISIS 278527; ISIS 278528; ISIS 278529; ISIS 278530; ISIS 278531; ISIS 278532; ISIS 278533; ISIS 278534; ISIS 278535; ISIS 27864; LYSINE DERIVATIVE; OLIGOMER; PEPTIDE DERIVATIVE; PEPTIDE NUCLEIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; MESSENGER RNA;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; BIOACCUMULATION; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG SPECIFICITY; GENETIC TRANSCRIPTION; IMMUNOMODULATION; MACROPHAGE; MOUSE; NONHUMAN; NUCLEIC ACID ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INDUCTION; PROTEIN PROCESSING; RECEPTOR DOWN REGULATION; TERMINAL SEQUENCE; VALIDATION PROCESS; ALTERNATIVE RNA SPLICING; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; CHEMISTRY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; EXON; FEMALE; FLOW CYTOMETRY; GENETICS; METABOLISM; PROTEIN TERTIARY STRUCTURE; REPRODUCIBILITY; TIME; TUMOR CELL LINE;

MURINAE;

ALTERNATIVE SPLICING; ANIMALS; ANTIGENS, CD40; CELL LINE, TUMOR; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; EXONS; FEMALE; FLOW CYTOMETRY; INTERLEUKIN-12; MACROPHAGES; MICE; MICE, INBRED C57BL; PEPTIDE NUCLEIC ACIDS; PROTEIN STRUCTURE, TERTIARY; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; TIME FACTORS;

EID: 2542610648     PISSN: 03051048     EISSN: None     Source Type: Journal    
DOI: 10.1093/nar/gkh584     Document Type: Article

References (29)

1. Grewal,I.S. and Flavell,R.A. (1998) CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol., 16, 111-135.
2. Kehry,M.R. (1996) CD40-mediated signaling in B cells. Balancing cell survival, growth and death. J. Immunol., 156, 2345-2348.
3. Noelle,R.J. (1996) CD40 and its ligand in host defense. Immunity, 4, 415-419.
4. Armitage,R.J., Fanslow,W.C., Strockbine,L., Sato,T.A., Clifford,K.N., Macduff,B.M., Anderson,D.M., Gimpel,S.D., Davis-Smith,T., Maliszewski,C.R. et al. (1992) Molecular and biological characterization of a marine ligand for CD40. Nature, 357, 80-82.
5. Henn,V., Slupsky,J.R., Grafe,M., Anagnostopoulos,I., Forster,R., Muller-Berghaus,G. and Kroczek,R.A. (1998) CD40 ligand on activated platelets triggers an inflammatory reaction on endothelial cells. Nature, 391, 591-594.
6. Noelle,R.J., Roy,M., Shepherd,D.M., Stamenkovic,I., Ledbetter,J.A. and Aruffo,A. (1992) A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation on B cells. Proc. Natl Acad. Sci. USA, 89, 6550-6554.
7. Jumper,M.D., Nishioka,Y., Davis,L.S., Lipsky,P.E. and Meek,K. (1995) Regulation of human B cell function by recombinant CD40 ligand and other TNF-related ligands. J. Immunol., 155, 2369-2378.
8. Kawabe,T., Naka,T., Yoshida,K., Tanaka,T., Fujiwara,H., Suematsu,S., Yoshida,N., Kishimoto,T. and Kikutani,H. (1994) The immune response in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity, 1, 167-178.
9. Crooke,S.T. (1999) Molecular mechanisms of action of antisense drugs. Biochim. Biophys. Acta, 1489, 31-43.
10. Zamore,P.D. (2002) Ancient pathways programmed by small RNAs. Science, 296, 1265-1269.
11. Elbashir,S.M., Harborth,J., Lendeckel,W., Yalcin,A., Weber,K. and Tuschl,T. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 411, 494-498.
12. Geary,R.S., Watanabe,T.A., Truong,L., Freier,S., Lesnik,E.A., Sioufi,N.B., Sasmor,H., Manoharan,M. and Levin,A.A. (2001) Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J. Pharmacol. Exp. Ther., 296, 890-897.
13. Yu,R.Z., Zhang,H., Geary,R.S., Graham,M., Masarjian,L., Lemonidis,K., Crooke,R., Dean,N.M. and Levin,A.A. (2001) Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice. J. Pharmacol. Exp. Ther., 296, 389-395.
14. Henry,S., Stecker,K., Brooks,D., Monteith,D., Conklin,B. and Bennett,C.F. (2000) Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J. Pharmacol. Exp. Ther., 292, 468-479.
15. Zhang,R., Lu,Z., Zhao,H., Zhang,X., Diasio,R.B., Habus,I., Jiang,Z., Iyer,R.P., Yu,D. and Agrawal,S. (1995) In vivo stability, disposition and metabolism of a 'hybrid' oligonucleotide phosphorothioate in rats. Biochem. Pharmacol., 50, 545-556.
16. Zhang,R., Iyer,R.P., Yu,D., Tan,W., Zhang,X., Lu,Z., Zhao,H. and Agrawal,S. (1996) Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration. J. Pharmacol. Exp. Ther., 278, 971-979.
17. McMahon,B.M., Mays,D., Lipsky,J., Stewart,J.A., Fauq,A. and Richelson,E. (2002) Pharmacokinetics and tissue distribution of a peptide nucleic acid after intravenous administration. Antisense Nucleic Acid Drug Dev., 12, 65-73.
18. Braasch,D.A. and Corey,D.R. (2001) Synthesis, analysis, purification and intracellular delivery of peptide nucleic acids. Methods, 23, 97-107.
19. Koppelhus,U. and Nielsen,P.E. (2003) Cellular delivery of peptide nucleic acid (PNA). Adv. Drug Delivery Rev., 55, 267-280.
20. Gait,M.J. (2003) Peptide-mediated cellular delivery of antisense oligonucleotides and their analogues. Cell. Mol. Life Sci., 60, 844-853.
21. Sazani,P., Gemignani,F., Kang,S.H., Maier,M.A., Manoharan,M., Persmark,M., Bortner,D. and Kole,R. (2002) Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotechnol., 20, 1228-1233.
22. Sazani,P., Kang,S.H., Maier,M.A., Wei,C., Dillman,J., Summerton,J., Manoharan,M. and Kole,R. (2001) Nuclear antisense effects of neutral anionic and cationic oligonucleotide analogs. Nucleic Acids Res., 29, 3965-3974.
23. Christensen,L., Fitzpatrick,R., Gildea,B., Petersen,K.H., Hansen,H.F., Koch,T., Egholm,M., Buchardt,O., Nielsen,P.E., Coull,J. et al. (1995) Solid-phase synthesis of peptide nucleic acids. J. Peptide Sci., 1, 175-183.
24. Koch,T., Hansen,H.F., Andersen,P., Larsen,T., Batz,H.G., Otteson,K. and Oerum,H. (1997) Improvements in automated PNA synthesis using Boc/Z monomers. J. Peptide Res., 49, 80-88.
25. Taylor,J., Zhang,Q., Wyatt,J. and Dean,N. (1999) Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat. Biotechnol., 17, 1097-1100.
26. Baker,B.F., Lot,S.S., Condon,T.P., Cheng-Flournoy,S., Lesnik,E.A., Sasmor,H.M. and Bennett,C.F. (1997) 2′-O-(2-methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J. Biol. Chem., 272, 11994-12000.
27. Chiang,M.Y., Chan,H., Zounes,M.A., Freier,S.M., Lima,W.F. and Bennett,C.F. (1991) Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J. Biol. Chem., 266, 18162-18171.
28. Karras,J.G., Maier,M.A., Lu,T., Watt,A. and Manoharan,M. (2001) Peptide nucleic acids are potent modulators of endogenous pre-mRNA splicing of the marine interleukin-5 receptor-a chain. Biochemistry, 40, 7853-7859.
29. Tone,M., Tone,Y., Fairchild,P.J., Wykes,M. and Waldmann,H. (2001) Regulation of CD40 function by its isoforms generated through alternative splicing. Proc. Natl Acad. Sci. USA, 98, 1751-1756.